Vico’s VO659 Receives EC’s Orphan Drug Designation for Spinocerebellar Ataxia

February 10, 2021 Auto Bot EC, receives, regulatory 0

Shots:

  • The EC granted ODD for VO659 for the treatment of spinocerebellar ataxia (SCA). The ODD was based on a EMA’s COMP positive opinion
  • The company previously received ODD in Huntington Disease The company focused on the development of RNA modulating therapies for rare neurological disorders
  • VO659 is an antisense oligonucleotide product, designed to suppress mutant proteins and slow or halt disease progression

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Polaris Partners

The post Vico’s VO659 Receives EC’s Orphan Drug Designation for Spinocerebellar Ataxia first appeared on PharmaShots.